Investment Thesis
BioAtla faces an imminent financial crisis with negative stockholders' equity of -$37.3M, indicating technical insolvency. The company has only $2.0M cash against a $5.3M annual burn rate, providing approximately 4-5 months of runway, and a critical liquidity crisis (0.15x current ratio) with zero revenue and significant operating losses.
Strengths
- Net losses narrowing YoY (+14.6% improvement) and EPS improving (+29.9% YoY) suggest operational efficiency gains
- Early-stage biotech business model is expected to operate at losses during pre-commercialization phases
- Insider activity observed (7 Form 4 filings in last 90 days) indicates management engagement
Risks
- Negative stockholders' equity of -$37.3M means liabilities exceed assets; company is technically insolvent
- Severe liquidity crisis with current ratio of 0.15x and only ~4 months of cash remaining at current burn rate
- Zero revenue with $9.3M annual operating losses and no clear near-term path to profitability
- Will require emergency capital raise or debt restructuring within months to avoid bankruptcy
- ROA of -74.1% indicates extreme asset inefficiency and value destruction
Key Metrics to Watch
- Cash runway and timing of next capital raise (survival metric)
- Operating burn rate trends and path to revenue generation
- Pipeline progress toward FDA approval or commercial partnerships
- Debt restructuring activities or dilutive equity offerings
- Form 4 insider activity patterns (indicator of management confidence/exit activity)
Financial Metrics
Revenue
0.0
Net Income
-6.3M
EPS (Diluted)
$-4.22
Free Cash Flow
-5.3M
Total Assets
8.6M
Cash
2.0M
Profitability Ratios
Gross Margin
N/A
Operating Margin
N/A
Net Margin
N/A
ROE
N/A
ROA
-74.1%
FCF Margin
N/A
Balance Sheet & Liquidity
Current Ratio
0.15x
Quick Ratio
0.15x
Debt/Equity
N/A
Debt/Assets
535.5%
Interest Coverage
N/A
Long-term Debt
N/A
Disclaimer: This analysis is generated by AI based on publicly available SEC EDGAR filings.
It does not include stock price data and should not be considered financial advice.
All fundamental data is sourced from SEC public domain filings.
Always conduct your own research before making investment decisions.
Data Source: SEC EDGAR |
Analysis Date: 2026-05-16T06:47:02.690394 |
Data as of: 2026-03-31 |
Powered by Claude AI